LY 3478045
Alternative Names: LY-3478045Latest Information Update: 28 Mar 2024
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Unspecified in USA (PO)
- 17 Feb 2020 Preclinical trials in Unspecified in USA (PO)
- 17 Feb 2020 Eli Lilly plans a phase I trial in Healthy volunteers (Monotherapy, Combination Therapy) in USA (PO) (NCT04270370)